当前位置: X-MOL 学术Am. J. Cardiovasc. Drugs › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Treating Acute Decompensated Heart Failure in Patients with COVID-19 Using Intravenous Nitroglycerin in 5% Glutathione
American Journal of Cardiovascular Drugs ( IF 2.8 ) Pub Date : 2021-03-22 , DOI: 10.1007/s40256-021-00474-w
Wayne Kaesemeyer 1 , Tatsiana Suvorava 2
Affiliation  

The purpose of this current opinion article is to illustrate a novel approach to the treatment of acute decompensated heart failure (ADHF) in coronavirus disease 2019 (COVID-19) patients. The approach described herein relies on a reformulation of intravenous nitroglycerin in 5% glutathione, itself novel, and is felt to have the potential to not only improve the rate of resolution of ADHF, but also reduce the risk of complications of heart failure seen in patients with COVID-19.



中文翻译:

静脉注射含 5% 谷胱甘肽的硝酸甘油治疗 COVID-19 患者的急性失代偿性心力衰竭

这篇当前观点文章的目的是说明一种治疗 2019 年冠状病毒病 (COVID-19) 患者急性失代偿性心力衰竭 (ADHF) 的新方法。本文描述的方法依赖于在 5% 谷胱甘肽中重新配制静脉注射硝酸甘油,这本身是新颖的,并且被认为有可能不仅提高 ADHF 的消退率,而且降低患者出现心力衰竭并发症的风险与 COVID-19。

更新日期:2021-03-22
down
wechat
bug